News >

Update Sustains Olaparib/Cediranib PFS Benefit in Ovarian Cancer

Wayne Kuznar
Published: Friday, Jun 09, 2017

Joyce F. Liu, MD, MPH

Joyce F. Liu, MD, MPH

In follow-up results to data first presented in December 2016, investigators found that the combination of olaparib (Lynparza) and cediranib maleate continued to show superior progression-free survival (PFS) compared with olaparib alone for women with BRCA-negative recurrent platinum-sensitive ovarian cancer.1

Liu said that investigators are recruiting patients for phase III trials of the combination in both the platinum-sensitive and platinum-resistant settings. “It is important that we are going to be looking at the biomarkers to help distinguish whether it is the non-carriers of germline BRCA mutations who are going to benefit the most from an antiangiogenic and a PARP inhibitor.”

References

  1. Liu J, Barry WT, Birrer M, et al. Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. J Clin Oncol. 2017;35 (suppl; abstr 5535).
  2. Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15:1207-1214.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x